Olutasidenib, sold under the brand name Rezlidhia, is an
anticancer medication
Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs (list of chemotherapeutic agents, chemotherapeutic agents or alkylating agents) in a standard chemotherapy re ...
used to treat relapsed or refractory
acute myeloid leukemia
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with haematopoiesis, normal blood cell production. Sympt ...
with a susceptible IDH1 mutation.
[ ] Olutasidenib is an
isocitrate dehydrogenase-1 (IDH1) inhibitor.
It is taken
by mouth
Oral administration is a route of administration whereby a substance is taken through the Human mouth, mouth, swallowed, and then processed via the digestive system. This is a common route of administration for many medications.
Oral administ ...
.
The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.
Olutasidenib was approved for medical use in the United States in December 2022,
based on the phase 1 results of a phase 1/2 trial.
Medical uses
Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Society and culture
Names
Olutasidenib is the international nonproprietary name.
References
Further reading
*
*
External links
*
{{Portal bar , Medicine
Antineoplastic drugs
Orphan drugs
Nitriles
2-Pyridones
Chloroarenes
2-Quinolones